ONCOTELIC THERAPEUTCS INC - OTLC STOCK NEWS

Oncotelic Therapeutics (OTCQB:OTLC) recently announced its plans to present studies on its TGF-β program at the AACR Annual Meeting 2022, highlighting the correlation between TGF-β expression and immune evasion in cancer and COVID-19.

The company's lead product, OT-101, has shown efficacy in over six clinical trials for solid tumors and a completed phase 2 trial against COVID-19. OT-101 is currently involved in a phase 1b trial combined with IL-2 and several upcoming trials with pembrolizumab.

Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced that Dr. Anthony E. Maida, Chief Clinical Officer, will present at the Evolution Summit in Los Angeles. Dr. Maida, an expert in immunotherapy, will discuss becoming truly patient-centric in healthcare. His career includes leading clinical research and raising over USD 200 million for biotech firms. Oncotelic focuses on developing TGF-β immunotherapies for late-stage cancers and has a promising drug candidate, OT-101. The company also acquired AL-101 for treating Parkinson's disease and erectile dysfunction.

Oncotelic Therapeutics (OTLC) announced Dr. Vuong Trieu's presentation at the MedInvest Pharmaceuticals and Biotechnology Investor Conference from March 28 - April 1, 2022. The company aims to reveal a Joint Venture with Golden Mountain Partners, which will focus on drug development and a new manufacturing facility. Oncotelic's lead drug, OT-101, has shown promising results in various clinical trials, including efficacy against solid tumors and COVID-19. The JV aims to secure funding for advancing Oncotelic's portfolio towards market approval.

Oncotelic Therapeutics (OTLC) is advancing its lead candidate, OT-101, an RNA therapeutic targeting TGF-β, having completed over six clinical trials demonstrating good efficacy against solid tumors. OT-101 is currently in a phase 1b trial combined with IL-2, with additional trials using pembrolizumab in development. The company is preparing to announce a joint venture with Golden Mountain Partners at the upcoming MedInvest Conference. This partnership aims to bolster Oncotelic's oncology drug portfolio and secure funding for future developments.

Oncotelic Therapeutics (OTLC) announced the development of OT-101, its RNA therapeutic targeting TGF-β, which has shown good efficacy in over six clinical trials against solid tumors. Currently, OT-101 is in a phase 1b trial combined with IL-2 and is being tested alongside pembrolizumab in multiple trials. The company is set to present its immunotherapy pipeline at BiotechGate Digital Partnering from Feb 7-11, 2022, aiming for transformative outcomes in treating high-TGF solid tumors. OT-101 has also shown efficacy against COVID-19 in a completed phase 2 trial.

Oncotelic Therapeutics (OTCQB:OTLC) has submitted a clinical study protocol to the US FDA for a Phase 1 trial of CA4P combined with pembrolizumab for melanoma treatment. This multicenter, open-label study aims to assess the safety and initial efficacy of CA4P in patients with recurrent metastatic melanoma. CA4P has been previously evaluated in over 500 patients across 17 studies. The trial leverages CA4P's potential synergy with checkpoint inhibitors and seeks to gain marketing approval for CA4P in a Rare Pediatric Disease.

Oncotelic Therapeutics, Inc. (OTCQB:OTLC) has announced a significant finding in its analysis of SARS-CoV-2, identifying the open reading frame 8 (ORF8) as a critical factor in the evolution of Delta and Omicron variants. The study revealed that higher serum levels of ORF8 in COVID-19 patients correlate with increased fatality rates. The company aims to leverage this information to develop therapeutics and vaccines targeting ORF8 as the virus mutates further. This analysis indicates an urgent need for ongoing innovation in COVID-19 treatment strategies.

Oncotelic Therapeutics (OTCQB:OTLC) announced that Dr. Anthony Maida will present at the 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit from January 25-27, 2022. The summit will showcase TGF-β inhibitors' potential in oncology and virology, particularly OT-101. This first-in-class anti-TGF-β RNA therapeutic has shown promise against relapsed cancer and is currently under evaluation for severe COVID-19 cases. Oncotelic aims to enhance treatment outcomes for cancer, emphasizing rare pediatric conditions.

Oncotelic Therapeutics (OTCQB:OTLC) has submitted a clinical study protocol to the US FDA for a Phase 2 trial (M201) of OT-101, its TGF-β inhibitor, combined with Anti-PD-1 (Pembrolizumab) for treating Malignant Pleural Mesothelioma (MPM). OT-101 is a first-in-class RNA therapeutic showing efficacy in cancer and has demonstrated activity against the SARS-CoV-2 virus. The trial aims to assess TGF-β inhibition's impact on various solid tumors while evaluating changes in the tumor microenvironment.